Novel monoclonal antibody-based therapies for acute myeloid leukemia

Morsink, Linde M.; Walter, Roland B.

doi:10.1016/j.beha.2019.05.002

Cited by 15 publications

(22 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above-mentioned antibodies interfere with the inhibition of cytotoxic activities of T and NK cells against tumor cells, therefore, they are regarded as "inhibitors" for inhibitory receptors. Gemtuzumab is an antibody against CD33, a member of inhibitory receptors, utilized for the treatment on hematopoietic malignancies [36]. This antibody binds to tumor cells without inducing activation of CD33.…”

Section: Kir2dl4 a Member Of The Kir Familymentioning

confidence: 99%

Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis

Kataoka

Ueshima

Hirata

et al. 2020

IJMS

View full text Add to dashboard Cite

Killer immunoglobulin-like receptor (KIR) 2DL4 (CD158d) was previously thought to be a human NK cell-specific protein. Mast cells are involved in allergic reactions via their KIT-mediated and FcɛRI-mediated responses. We recently detected the expression of KIR2DL4 in human cultured mast cells established from peripheral blood of healthy volunteers (PB-mast), in the human mast cell line LAD2, and in human tissue mast cells. Agonistic antibodies against KIR2DL4 negatively regulate the KIT-mediated and FcɛRI-mediated responses of PB-mast and LAD2 cells. In addition, agonistic antibodies and human leukocyte antigen (HLA)-G, a natural ligand for KIR2DL4, induce the secretion of leukemia inhibitory factor and serine proteases from human mast cells, which have been implicated in pregnancy establishment and cancer metastasis. Therefore, KIR2DL4 stimulation with agonistic antibodies and recombinant HLA-G protein may enhance both processes, in addition to suppressing mast-cell-mediated allergic reactions.

show abstract

Section: Kir2dl4 a Member Of The Kir Familymentioning

confidence: 99%

Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis

Kataoka

Ueshima

Hirata

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Immunotherapy is use of biological substances (antigen/antibody, immunomodulators administration) to regulate host immune system in order to fulfill prophylactic and/or therapeutic purpose. Immunotherapy aims to trigger the immune power by directly (antigen based or active immunotherapy) or indirectly (antibody based or passive immunotherapy) [45,46]. This section describes various immunotherapeutic strategies of molecular medicine that have been reported for the parasitic diseases.…”

Section: Immunotherapeutic Approachmentioning

confidence: 99%

Molecular Medicines for Parasitic Diseases

Singh¹

2021

Methods in Molecular Medicine

View full text Add to dashboard Cite

Being the cause for significant amount of morbidities and mortalities, parasitic diseases remain the major challenge for the healthcare community due to the limitations associated with the current chemotherapeutics. Drug discovery/invention can be achieved by collaborative efforts of biotechnologists and pharmacists for identifying potential candidates and successfully turn them into medicine for improving the healthcare system. Although molecular medicine for disease intervention is still in its infancy, however, significant research works and successful trials in short span of time have made it broadly accepted among the scientific community. This chapter identifies different molecular medicine approaches for dealing with parasites that have been coming up on the horizon with the new technological advances in bioinformatics and in the field of omics. With the better understanding of the genomics, molecular medicine field has not only raised hopes to deal with parasitic infections but also accelerated the development of personalized medicine. This will provide a targeted approach for identifying the druggable targets and their pathophysiological importance for disease intervention.

show abstract

“…In phase 1, anti-CD25, anti-CD44 and anti-CD47 antibodies failed to obtain a significant response (177)(178)(179). Only a few minor studies without clear results for anti-CD45 radiolabeled antibodies have been reported.…”

Section: Monoclonal and Bispecific T-cells Engagers (Bite) Antibodiesmentioning

confidence: 99%

“…Compound CAR T-cells targeting CD33 and CD123 are in development, and exhibit pronounced anti-leukemic activity (213). Nevertheless, CD123 and CCL-1 compound CAR T-cells might be useful for LSC targeting with limited hematopoietic toxicity (36,177). Lastly, IL1RAP CAR T-cells have been described as having a potent effect on LSC in CML, and more recently in AML, without affecting healthy HSCs (214,215).…”

Section: T-cell Transfer Therapy a New Era In Cancer Immunotherapy Chmentioning

confidence: 99%

“…CD33-targeting with GO is currently the most advanced strategy available, but CD33-targeting is still under investigation, particularly to limit VOD, as described previously. Indeed the effect of several mAbs, with or without a conjugated drug, on CD25, CD38, CD44, CD45, CD47, CD70, CD123, CD157, FLT3, IL1RAP, and CCL-1, are being investigated ( 36 , 177 ). Only a few translations from preclinical models to clinical trials have shown a satisfactory response in AML clinical studies ( Table 3 ).…”

Section: Therapies In Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics

et al. 2020

View full text Add to dashboard Cite

Recent studies have provided several insights into acute myeloid leukemia. Studies based on molecular biology have identified eight functional mutations involved in leukemogenesis, including driver and passenger mutations. Insight into Leukemia stem cells (LSCs) and assessment of cell surface markers have enabled characterization of LSCs from hematopoietic stem and progenitor cells. Clonal evolution has been described as having an effect similar to that of microenvironment alterations. Such biological findings have enabled the development of new targeted drugs, including drug inhibitors and monoclonal antibodies with blockage functions. Some recently approved targeted drugs have resulted in new therapeutic strategies that enhance standard intensive chemotherapy regimens as well as supportive care regimens. Besides the progress made in adoptive immunotherapy, since allogenic hematopoietic stem cell transplantation enabled the development of new T-cell transfer therapies, such as chimeric antigen receptor T-cell and transgenic TCR T-cell engineering, new promising strategies that are investigated.

show abstract

Novel monoclonal antibody-based therapies for acute myeloid leukemia

Cited by 15 publications

References 118 publications

Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis

Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis

Molecular Medicines for Parasitic Diseases

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics

Contact Info

Product

Resources

About